Acticor Biotech

It is with great emotion that we announce today the liquidation proceedings of Acticor Biotech. Despite our efforts to refinance the company, the challenges faced in 2024 have led to this outcome. This decision marks the end of a journey of over 10 years dedicated to innovation in the field of cardiovascular emergencies, particularly with the development of glenzocimab. We have poured all our energy and conviction into the research and development of solutions capable of transforming the management of complex conditions such as ischemic stroke. While recent clinical results did not succeed in convincing investors, we remain confident in glenzocimab’s potential for other indications, such as myocardial infarction. We would like to express our deepest gratitude to all stakeholders who have supported us: employees, shareholders, clinicians, partners, and patients. Your trust and commitment have been the driving force behind this journey. This conclusion does not erase the lessons learned nor the contributions we have made to the scientific community. We hope that these foundations will inspire future projects. Thank you all for these years of collaboration and innovation. ✉️ Letter to shareholders : https://lnkd.in/ehNg7iKu 🔗 Press release link : https://lnkd.in/eajBW_G3

🚨 Acticor Biotech: Strategic Appointment and Clinical Developments! 🚨   We are sharing two major updates for Acticor Biotech :  🔹 Clinical Focus: Acticor Biotech is preparing the design for an upcoming GLORIA clinical trial, aimed at assessing glenzocimab's benefits in angioplasty for STEMI. Currently, 27 patients have been enrolled in the Phase 2b LIBERATE study, evaluating our innovative drug, glenzocimab, in the treatment of ST-Elevation Myocardial Infarction (STEMI).  🔗 : https://lnkd.in/edRtDvhX 🔹 Francois Guillet has been appointed as Chief Financial Officer. With his extensive experience in restructuring and international management, François will be a valuable asset in guiding Acticor Biotech through this strategic phase. We are thankful to Eric COHEN for his remarkable contributions since 2016, especially during Acticor's IPO. 🔗 : https://lnkd.in/ej3Y4Ukc #Biotech #innovation #clinicaldevelopment

🚀 Very happy to see our latest publication on GARDEN clinical trial investigating therapeutic GPVI inhibition in COVID-19 patients! Our study found that glenzocimab, when used with therapeutic heparin, did not increase bleeding or severe adverse events. However, its impact on COVID-19 ARDS was not conclusive. We want to take the opportunity to thank again all patients/family/nurse/caregivers and investigators that relentlessly committed to continue clinical trials even during the pandemic. As we continue to explore glenzocimab's potential in cardiovascular emergencies, we remain committed to advancing clinical research for better patient outcomes.   #ClinicalResearch #COVID19 #ARDS #GPVI #Glenzocimab #GARDEN #Publication 📄 Read the full paper here:

🎙️ Gilles Avenard, CEO of Acticor Biotech, is discussing ACTISAVE results and the future developments of Acticor Biotech, during an interview with Le Journal des Biotechs with Laurent Grassin.   🔬Deep-dive analysis into ACTISAVE phase 2/3 study results.   👨⚕️ New post-hoc analyses of ACTISAVE showing positive trends for glenzocimab in subpopulations of patients. 🚀 Continuation of ongoing clinical studies: Phase 2/3 GREEN in Ischemic stroke and Phase 2b LIBERATE in myocardial infarction   🚀 Discussing future designs for clinical trial with glenzocimab. 🔗 Link for the full interview (start at 22’25) : https://lnkd.in/e9D8ehsr #interview #glenzocimab #LeJournalDesBiotechs

[#GlenzoNews] Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies 🧠 👨⚕️ New analyses of ACTISAVE phase 2/3 study show positive trends for glenzocimab in subpopulations of patients 🔬Continuation of clinical studies: Phase 2/3 GREEN in Ischemic stroke and Phase 2b LIBERATE in myocardial infarction 🚀 Launch of GALICE, a Phase 2/3 study in severe ischemic stroke, sponsored by the Hôpital Fondation Adolphe de Rothschild and funded by a public grant (national PHRC1 in 2023) 🔗 Press release link : https://lnkd.in/eCWjewqS #PressRelease #Glenzocimab #ClinicalDevelopment

[#GlenzoCongress] 💡Curious about Acticor Biotech's latest updates and future developments ? Meet our CEO, Gilles Avenard & Sophie Binay, PhD, CSO and General Manager, at the BIO International Convention from June 3 to 6, 2024 🗓 📍 San Diego Convention Center - CA, United States 🌐 Register link : https://lnkd.in/gSXh3GTj #biotech #news #convention